Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37714168

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2023 Oct
First author
Saad F

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2023 Oct;24(10):1056-1057. doi: 10.1016/S1470-2045(23)00448-5.
    note
    Source null
    related pmid
    37797626
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2024 May;25(5):e180. doi: 10.1016/S1470-2045(24)00209-2.
    note
    Source null
    related pmid
    38697163
    relationship
    Erratum in

Authors and identifiers

  1. name
    Saad F
    type
    Author
  2. name
    Clarke NW
    type
    Author
  3. name
    Oya M
    type
    Author
  4. name
    Shore N
    type
    Author
  5. name
    Procopio G
    type
    Author
  6. name
    Guedes JD
    type
    Author
  7. name
    Arslan C
    type
    Author
  8. name
    Mehra N
    type
    Author
  9. name
    Parnis F
    type
    Author
  10. name
    Brown E
    type
    Author
  11. name
    Schlürmann F
    type
    Author
  12. name
    Joung JY
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Saad F
    type
    Author
  2. name
    Clarke NW
    type
    Author
  3. name
    Oya M
    type
    Author
  4. name
    Shore N
    type
    Author
  5. name
    Procopio G
    type
    Author
  6. name
    Guedes JD
    type
    Author
  7. name
    Arslan C
    type
    Author
  8. name
    Mehra N
    type
    Author
  9. name
    Parnis F
    type
    Author
  10. name
    Brown E
    type
    Author
  11. name
    Schlürmann F
    type
    Author
  12. name
    Joung JY
    type
    Author
bibliography ids
  1. nci-bib-7016b2bd2fec104bf2568031
book metadata
content sha256
0b5eb8bf30f8b042c55a683b7f8b9b49c35682e58be8d05d7b5bee2dc289ee41
document type
citation
dois
  1. 10.1016/S1470-2045(23)00382-0
electronic publication date
display
2023 Sep 12
precision
day
year
2023
evidence scope
bibliographic_metadata_only
id
pubmed:37714168
immutable id
pubmed:37714168@0b5eb8bf30f8b042c55a683b7f8b9b49c35682e58be8d05d7b5bee2dc289ee41
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
10
name
The Lancet. Oncology
nlm unique id
100957246
pages
1094-1108
volume
24
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2023 Oct;24(10):1056-1057. doi: 10.1016/S1470-2045(23)00448-5.
    note
    Source null
    related pmid
    37797626
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2024 May;25(5):e180. doi: 10.1016/S1470-2045(24)00209-2.
    note
    Source null
    related pmid
    38697163
    relationship
    Erratum in
outcomes validated
false
pmid
37714168
provenance
batch id
5329a5d0877ee70ecd11
provider
NCBI PubMed ESummary
record sha256
28cde0a56062b8eb7ab43a0d1f3a7c3801bf6207967eccaf2d104687431d3a1a
response sha256
bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
retrieved at
2026-09-09T23:48:15.763286+00:00
publication date
display
2023 Oct
precision
month
year
2023
publication types
  1. Journal Article
  2. Randomized Controlled Trial
  3. Research Support, Non-U.S. Gov't
  4. Clinical Trial, Phase III
  5. Multicenter Study
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/37714168/
title
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.

Preserved source evidence · Not medical advice